http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
혈장내 testosterone정량을 위한 화학발광 면역분석법 개발
박관하,김영길,우종규,최상훈,최민순 群山大學校 1997 論文集 Vol.24 No.-
The immunoassay monitored by the detection of chemiluminescence for the determination of plasma testosterone has been developed. The labelled antigen was testosterone-3-carboxymethyl oxime-aminobutylethyl isoluminol. Following an antigen-antibody reaction, the bound fraction was separated from free fraction by the addition of dextran-coated charcoal followed by a centrifugation. Sodium hydroxide (5N) was added and the mixture incubated for 1hr at 60℃. Luminescence is initiated by oxidation of the label with microperoxidase-hydrogen peroxide and the signal integrated for 10sec. The light yield was inversely proportional to the concentration of testosterone in the standard of samples. This method appeared to show a similar sensitivity, specificity, precision, and an accuracy compared to the conventional radioimmunoassay(RIA) with a tritiated antigen. The results obtained from the analysis of plasma testosterone were in good agreement with the values derived by RIA(γ=0.97)
가상현실 기법의 활용이 지식 성취도 향상에 미치는 효과 : 눈의 구조와 기능 내용을 중심으로 The Structure and Function of Eye
심규철,류수정,김현섭,김희수,박영철 한국과학교육학회 2003 한국과학교육학회지 Vol.23 No.1
The purpose of present study was to develop teaching-learning materials based virtual reality technology(VRT), and to examine the effect of it on the knowledge achievement of biology. Authoring tool of virtual reality(VR) was 3D Webmaster made in Superscape Ltd., United Kingdom. Educational materials was developed for the structure and function of eye of life field in the 10th science. It was learner-directed and interactive educational material using the Web-based and desktop VR. The result showed a meaningful improvement on the achievement. Using 3D VR shows the potential of available education media in the next generation as science teaching-aided material, which especially was efficient in the understanding and perception of abstract or difficult to direct experience learning contents.
육근철,이희복,류해일,김현섭,김희수,박달원,심규철,박종석,신영숙,박상태,변두원,김태균 공주대학교 과학교육연구소 2002 과학교육연구 Vol.33 No.-
21세기의 정보화 산업사회와 지식기반 사회에서 우리의 아이들이 자신의 목소리로 세계 속에서 살아가게 하기 위해서는 다른 사람과 다른 아이디어를 낼 수 있도록 교육의 틀을 바꾸지 않으면 안된다. 다라서 21세기의 미래 사회를 살아갈 학생들을 가르치는 교육의 현장 역시 창의적인 인간을 길러낼 수 있도록 변해야 한다. 즉, 미래 사회를 대비하기 위해서는 각 개인의 개성을 존중하는 분위기에서 창의적인 능력을 지닌 인간을 양성해야 한다는 것을 의미한다. 따라서, 학교 안에서의 교육뿐만이 아니라 학교 밖에서도 다양한 학습 경험을 통해서 교육 과정이 추구하는 인간상을 구현할 수 있도록 활동할 수 있는 기회가 학생들에게 제공되어야 한다. 창의력을 발휘하여 문제를 해결하는 능력을 기르기 위해서는 개별적이 아닌 여러 명의 동료가 주어진 과제를 해결할 수 있는 기회를 갖고 짧은 시간이 아닌 장시간 동안 고민하고 그 해결책을 찾는 활동을 가질 기회가 필요하다. In order to educate our students with their special talents for the informational and knowledge based age expected in the 21st century, we must improve our educational programs such that students are able to create their own fresh ideas. Hence the present educational environment should be changed such that they are willing to respect others' characters and personality with their own original ideas. Therefore, we must make them have the opportunity that they can acquire many experiences through the school education and the social education program, so that they may grow up to the person with the humanity and creativity. In this study we have suggested new educational program where students engage themselves in long term research projects with collaboration of the team and creativity of individuals.
비대상성 간경변증 환자에서 라미부딘 장기투여의 효능과 안전성에 관한 연구
박태욱,박영민,배시현,장정원,남순우,최종영,윤승규,조세현,양진모,한남익,안병민,이영석,이창돈,박두호 대한간학회 2002 Clinical and Molecular Hepatology(대한간학회지) Vol.8 No.4
목적: 본 연구는 비대상성 간경변증 환자에서 라미부딘의 효과를 알아보고자 전향적 연구를 시 행하였다. 대상과 방법: 임상적 기준에 따라 B형 간염바이러스에 의한 비대상성 간경변증으로 진단 된 환자중 라미부딘을 하루 75-150 mg 씩 12 개월 이상 치료한 21 명을 치료군 (남자 14명, 여자 7 명 평균연령 50세, 범위 34-73세, Child-Pugh; B 등급 17명, C 등급 4명)으로 하였고, 보존적인 치료만으로 추적 검사한 20명을 대조군 (남자 17명, 여 자 3명 평균연령 50세, 범위 39-61세, Child-Pugh; B 등급 15명, C 등급 5명)으로 정하고 전향적 연구를 시행하였다. 치료 전후로 HBV DNA 정량, HBeAg 정량, 혈액학적/생화학적 간기능 검사, Child-Pugh 점수 등의 소견을 비교 분석하였다. 치료 반응의 기준은 HBV DNA 와 HBeAg 음전화, ALT 치 정상화 여부에 따라 반응군, Breakthrough군, 무반응군으로 정하였고, 임상적 호전의 정의는 Child-Pugh 점수가 2점 이상 감소한 경우로 하였 다. 결과: 평균 관찰기간은 17개월 (범위 12개월 -26개월)이었다. 라미부딘 치료에 대한 반응군은 62% (13/21), Breakthrough군은 33% (7/21) 이고, 무반응군은 5% (1/21)였다. 평균 Child-Pugh 점수는 치료전 8.6점에서 관찰 종료시점에 6.0점으로 호전되었지만, 대조군에서는 8.7점에서 10점으로 악화되었다. Child-Pugh 점수가 2점 이상 호전된 경우도 치료군에서 71% (15/21)였지만 대조군에서 5% (1/20)였다. HBeAg의 음전율은 치료군에서 31% (5/16)였으나, 대조군에서는 음전화예는 없었다. 치료 후 Child-Pugh 등급 A 14명, B 6명 그 리고 C가 1명이었지만, 대조군에서는 등급 B환자 15명 중 1명만이 등급 A로 호전되고 8명의 환자가 등급 C로 악화되었고, 등급 C 환자에서 임상적으로 호전된 경우는 없었다. 치료군에서 혈청 알부민, 프로트롬빈 시간, AFP 수치와 Child-Pugh 점수의 호전은 통계적으로 유의하였다 (p<0.05). 결론: 비 대상성 간경변증 환자에서 라미부딘의 치료효과는 매우 고무적이며, 특히 일부 Breakthrough군이나 무반응군에서도 간기능 호전 소견을 관찰할 수 있어 향후 이에 대한 대규모 연구가 이루어져야 할 것으로 생각된다. Background/Aims: Lamivudine use in patients with decompensated cirrhosis B has been reported to improve the hepatic function and often delay the need for liver transplantation. In the present study, we evaluated the efficacy and safety of long-term lamivudine therapy in patients with decompensated cirrhosis by comparative study using a matched, untreated cohort. Methods: 41 patients with decompensated cirrhosis B were included for this study (31 male and 10 female; mean age, 50 years; mean observation period, 18 months). They were divided into two groups: a lamivudine treatment group and an untreated control group. 21 patients in the treatment group were treated with lamivudine 75 or 150 mg daily for at least 12 months. Biochemical and serologic markers were evaluated at two to three-month intervals for all patients. Clinical improvement was defined by a decrease in the Child-Pugh score of at least 2 points. Results: During the observation period, 62% (13/21) was responders, 33% (7/21) was breakthrough, and 5% (1/21) was non-responder in the treated group. The mean Child-Pugh score was significantly improved from 8.6 to 6.0 in the treatment group, but aggravated from 8.7 to 10.0 in the control group during the follow-up. The HBeAg seroconversion rate was 31% in the treatment group (5/16) and none in the control group (0/14). Clinical improvement was observed in fifteen of 21 in the treatment group (71%) and only one of 20 in the control group (5%). According to the treatment responses, clinical improvement was observed in ten of 13 responders (77%), four of 7 breakthrough (57%), and one non-responder. Conclusions: The long-term administration of lamivudine for patients with decompensated cirrhosis B is effective and safe, although breakthrough and non-response occurred in some patients.(Korean J Hepatol 2002;8:428-435)
Park, Hye-Kyung,Cho, Min Kyoung,Park, Hee Young,Kim, Ki Uk,Kim, Yun Seong,Lee, Min Ki,Park, Soon Kew,Kim, Dong-Hee,Yu, Hak Sun Informa Healthcare 2012 The Journal of asthma Vol.49 No.1
<P><I>Background</I>. In a previous study, we demonstrated that the human macrophage migration inhibitory factor (MIF)-like protein (As-MIF) isolated from helminths could inhibit allergic airway inflammation via the recruitment of CD4<SUP>++</SUP>CD25<SUP>++</SUP>Foxp3<SUP>++</SUP> T cells. <I>Objective</I>. To evaluate the clinical importance of As-MIF as an antiasthma drug, we evaluated immune responses after recombinant As-MIF (rAs-MIF) treatment in peripheral blood mononuclear cell (PBMC) cultures. <I>Methods</I>. PBMC was isolated from 10 patients with atopic asthma, 8 patients with nonatopic asthma, and 12 nonatopic healthy subjects, and various concentrations of rAs-MIF were transferred into the PBMC culture medium. After 3 days, we measured the levels of T helper 2 and T helper 1 cytokines via ELISA. <I>Results</I>. In atopic asthma, IL-4 and IL-5 production was significantly reduced in the PBMC cultures after rAs-MIF treatment. These inhibitory effects were not observed in the nonatopic asthma group. By way of contrast, IL-10 production in the PMBC cultures was significantly increased after rAs-MIF treatment in all experimental groups. <I>Conclusion</I>. The results of this study are similar to those previously reported in a mouse study, suggesting that As-MIF might be a candidate for the specific treatment of asthma.</P>